Publications by authors named "Puyuan Xing"

Claim this Profile
A
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Yuankai Shi, Dongqing Lv, Weineng Feng, Shuoyan Liu, Puyuan Xing

Signal Transduct Target Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients.
Jing Wang, Wei Su, Qin Chen, Jiemin Zhou, Xinyue Wang, Puyuan Xing

Front Microbiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNAJA: emerging targets for anti-tumor therapy.
Lige Wu, Puyuan Xing, Junling Li

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations.
Hong-Shuai Li, Cheng-Ming Liu, Su-Fei Zheng, Peng Wu, Han-Yan Xu, Pu-Yuan Xing

Cell Rep Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Immune-Combination Therapy for Driver Gene-Negative NSCLC With Brain Metastases: Real-World Outcomes.
Mengxing You, Lige Wu, Jiayu Liu, Hanqi Yuan, Zihe Wang, Puyuan Xing

Thorac Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.
Ziyi Xu, Yan Li, Lin Wang, Xuezhi Hao, Jianming Ying, Puyuan Xing

Expert Rev Anticancer Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study.
Puyuan Xing, Xingxiang Pu, Yu Zhou, Ziling Liu, Yu Yao

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.
Hanqi Yuan, Zihua Zou, Xuezhi Hao, Yan Li, Junling Li, Puyuan Xing

Thorac Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteogenomic Characterization of High-Grade Lung Neuroendocrine Carcinoma Deciphers Molecular Diversity and Potential Biomarkers of Different Histological Subtypes in Chinese Population.
Zicheng Zhang, Xi Wu, Siqi Bao, Xujie Sun, Fan Yang, Puyuan Xing

Research (Wash D C)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer.
Mengxing You, Jiayu Liu, Fei Teng, Lige Wu, Haifeng Qin, Puyuan Xing

Transl Lung Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecirasib in KRAS-mutated nonsmall-cell lung cancer: a phase 2b trial.
Yuankai Shi, Jian Fang, Ligang Xing, Yu Yao, Jian Zhang, Puyuan Xing, Xingya Li

Nat Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review).
Jia-Yu Liu, Shou-Zheng Wang, Han-Qi Yuan, Jun-Ling Li, Pu-Yuan Xing

Oncol Lett· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma.
Dantong Sun, Helei Hou, Feiyue Feng, Weizheng Wu, Jingyu Tan, Puyuan Xing

Exp Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.
Zihua Zou, Lige Wu, Xuezhi Hao, Yan Li, Li Liang, Puyuan Xing

Thorac Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial neural network systems to predict the response to sintilimab in squamous-cell non-small-cell lung cancer based on data of ORIENT-3 study.
Tongji Xie, Guangyu Fan, Le Tang, Puyuan Xing, Yuankai Shi

Cancer Immunol Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance and underlying mechanisms of STING in lung adenocarcinoma.
Haohua Zhu, Yufeng Cao, Jingyu Lu, Lei Guo, Rongrong Luo, Puyuan Xing, Xingsheng Hu

Chin Med J (Engl)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas.
Yan Li, Tongji Xie, Shouzheng Wang, Lin Yang, Xuezhi Hao, Xingsheng Hu, Puyuan Xing

Signal Transduct Target Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer.
Puyuan Xing, Shanbing Wang, Minghong Bi, Yong Liu, Jia Zeng

EClinicalMedicine· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China.
Shouzheng Wang, Jiayu Liu, Yan Wang, Ying Hu, Ziling Liu, Puyuan Xing

Chin J Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.
Ruyun Gao, Ning Lou, Lin Li, Tongji Xie, Puyuan Xing

J Transl Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.
Lige Wu, Zihua Zou, Yan Li, Xuezhi Hao, Jianming Ying, Puyuan Xing

J Transl Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Shasha Wang, Xuezhi Hao, Liyuan Dai, Ning Lou, Guangyu Fan, Puyuan Xing

Lung Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Qiaoyun Tan, Ruyun Gao, Xiaomei Zhang, Jianliang Yang, Puyuan Xing

Cancer Immunol Immunother· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MDM2 in malignancies is a promising strategy for overcoming resistance to anticancer immunotherapy.
Dantong Sun, Haili Qian, Junling Li, Puyuan Xing

J Biomed Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced -mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.
Dongming Zhang, Xiaoyan Liu, Fangfang Shen, Dahai Zhao, Yuequan Shi, Xiaoxing Gao, Puyuan Xing

Transl Lung Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis